Head to Head Contrast: Kyverna Therapeutics (KYTX) versus Its Competitors

Kyverna Therapeutics (NASDAQ:KYTX) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare Kyverna Therapeutics to related companies based on the strength of its analyst recommendations, profitability, risk, earnings, dividends, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings for Kyverna Therapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	0	1	4	1	3.00
Kyverna Therapeutics Competitors	1924	5382	13923	296	2.58

Kyverna Therapeutics presently has a consensus target price of $18.40, suggesting a potential upside of 820.00%. As a group, “Biological products, except diagnostic” companies have a potential upside of 102.90%. Given Kyverna Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Kyverna Therapeutics is more favorable than its competitors.

Insider and Institutional Ownership

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Kyverna Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kyverna Therapeutics	$7.03 million	-$60.37 million	-0.58
Kyverna Therapeutics Competitors	$574.62 million	-$70.96 million	-0.15

Kyverna Therapeutics’ competitors have higher revenue, but lower earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Kyverna Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-51.12%	-37.91%
Kyverna Therapeutics Competitors	-2,185.76%	-161.46%	-40.62%

Summary

Kyverna Therapeutics beats its competitors on 8 of the 12 factors compared.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.